HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $27

Benzinga · 2d ago
HC Wainwright & Co. analyst Robert Burns maintains Immix Biopharma (NASDAQ:IMMX) with a Buy and raises the price target from $25 to $27.